Literature DB >> 9600207

Caprine mucopolysaccharidosis-IIID: clinical, biochemical, morphological and immunohistochemical characteristics.

M Z Jones1, J Alroy, P J Boyer, K T Cavanagh, K Johnson, D Gage, J Vorro, J A Render, R S Common, R A Leedle, C Lowrie, P Sharp, S S Liour, B Levene, H Hoard, R Lucas, J J Hopwood.   

Abstract

Several animal models have been developed for the mucopolysaccharidoses (MPSs), a group of lysosomal storage disorders caused by lysosomal hydrolase deficiencies that disrupt the catabolism of glycosaminoglycans (GAG). Among the MPS, the MPS-III (Sanfilippo) syndromes lacked an animal counterpart until recently. In this investigation of caprine MPS-IIID, the clinical, biochemical, morphological, and immunohistochemical studies revealed severe and mild phenotypes like those observed in human MPS III syndromes. Both forms of caprine MPS IIID result from a nonsense mutation and consequent deficiency of lysosomal N-acetylglucosamine 6-sulfatase (G6S) activity and are associated with tissue storage and urinary excretion of heparan sulfate (HS). Using special stains, immunohistochemistry, and electron microscopy, secondary lysosomes filled with GAG were identified in most tissues from affected goats. Primary neuronal accumulation of HS and the secondary storage of gangliosides were observed in the central nervous system (CNS) of these animals. In addition, morphological changes in the CNS such as neuritic expansions and other neuronal alterations that may have functional significance were also seen. The spectrum of lesions was greater in the severe form of caprine MPS IIID and included mild cartilaginous, bony, and corneal lesions. The more pronounced neurological deficits in the severe form were partly related to a greater extent of CNS dysmyelination. These findings demonstrate that caprine MPS IIID is a suitable animal model for the investigation of therapeutic strategies for MPS III syndromes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9600207     DOI: 10.1097/00005072-199802000-00006

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  12 in total

1.  Lessons learnt from animal models: pathophysiology of neuropathic lysosomal storage disorders.

Authors:  Kim M Hemsley; John J Hopwood
Journal:  J Inherit Metab Dis       Date:  2010-05-07       Impact factor: 4.982

2.  Caprine mucopolysaccharidosis IIID: a preliminary trial of enzyme replacement therapy.

Authors:  E Downs-Kelly; M Z Jones; J Alroy; K T Cavanagh; B King; R E Lucas; J C Baker; S A Kraemer; J J Hopwood
Journal:  J Mol Neurosci       Date:  2000-12       Impact factor: 3.444

3.  A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type I.

Authors:  Li Ou; Michael J Przybilla; Ozan Ahlat; Sarah Kim; Paula Overn; Jeanine Jarnes; M Gerard O'Sullivan; Chester B Whitley
Journal:  Mol Ther       Date:  2020-04-08       Impact factor: 11.454

4.  Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase.

Authors:  H H Li; W H Yu; N Rozengurt; H Z Zhao; K M Lyons; S Anagnostaras; M S Fanselow; K Suzuki; M T Vanier; E F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

5.  Ataxia is the major neuropathological finding in arylsulfatase G-deficient mice: similarities and dissimilarities to Sanfilippo disease (mucopolysaccharidosis type III).

Authors:  Björn Kowalewski; Peter Heimann; Theresa Ortkras; Renate Lüllmann-Rauch; Tomo Sawada; Steven U Walkley; Thomas Dierks; Markus Damme
Journal:  Hum Mol Genet       Date:  2014-12-01       Impact factor: 6.150

6.  Recombinant caprine 3H-[N-acetylglucosamine-6-sulfatase] and human 3H-[N-acetylgalactosamine-4-sulfatase]: plasma clearance, tissue distribution, and cellular uptake in the rat.

Authors:  M Z Jones; L K Brumfield; B M King; J J Hopwood; S Byers
Journal:  J Mol Neurosci       Date:  1998-12       Impact factor: 3.444

7.  A model of mucopolysaccharidosis IIIB (Sanfilippo syndrome type IIIB): N-acetyl-alpha-D-glucosaminidase deficiency in Schipperke dogs.

Authors:  N M Ellinwood; P Wang; T Skeen; N J H Sharp; M Cesta; S Decker; N J Edwards; I Bublot; J N Thompson; W Bush; E Hardam; M E Haskins; U Giger
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

8.  Caprine mucopolysaccharidosis IIID: fetal and neonatal brain and liver glycosaminoglycan and morphological perturbations.

Authors:  Margaret Z Jones; Joseph Alroy; Erinn Downs-Kelly; Rebecca E Lucas; Stacey A Kraemer; Kevin T Cavanagh; Barbara King; John J Hopwood
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

9.  Assessment of dysmyelination with RAFFn MRI: application to murine MPS I.

Authors:  David Satzer; Christina DiBartolomeo; Michael M Ritchie; Christine Storino; Timo Liimatainen; Hanne Hakkarainen; Djaudat Idiyatullin; Silvia Mangia; Shalom Michaeli; Ann M Parr; Walter C Low
Journal:  PLoS One       Date:  2015-02-13       Impact factor: 3.240

Review 10.  Pain in Mucopolysaccharidoses: Analysis of the Problem and Possible Treatments.

Authors:  Sabrina Congedi; Marcello Orzalesi; Chiara Di Pede; Franca Benini
Journal:  Int J Mol Sci       Date:  2018-10-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.